IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience, Piazzale Brescia 20, Milano, 20149, Italy.
PhD Program in Neuroscience, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Neurol Sci. 2023 Feb;44(2):587-592. doi: 10.1007/s10072-022-06438-5. Epub 2022 Oct 6.
The present study aimed at evaluating the diagnostic properties of the Frontal Assessment Battery (FAB) in non-demented ALS patients by addressing the Edinburgh Cognitive Behavioural ALS Screen (ECAS) as the gold standard, as well as by examining the association between its administrability and scores with motor-functional measures.
N = 348 consecutive patients were administered the ECAS and FAB. Disease severity (ALSFRS-R), duration, progression rate (ΔFS), and stages (via King's and Milano-Torino systems) were considered. Administrability rates and prevalence of below-cut-off FAB scores were compared across clinical stages; regression models allowed to test whether, net of the ECAS-Total, motor features predicted the probability of the FAB not being administrable and of a defective FAB score. Intrinsic and post-test diagnostics were explored against a combined defective ECAS-Executive and ECAS-Fluency scores.
85.3% of patients managed to complete the FAB. FAB administrability rates decreased with advanced clinical stages, whereas the prevalence of below-cut-off FAB scores did not. The probability of the FAB not being administrable was predicted only by lower ALSFRS-R-bulbar and ALSFRS-R-upper-limb scores; no motor features, but the ECAS-Total, predicted a below-cut-off performance on the FAB. Raw and adjusted FAB scores showed high accuracy (AUC = .85 and .81, respectively) and good intrinsic and post-test properties.
The FAB is featured by optimal diagnostics for detecting executive deficits in ALS, provided that it can be administered according to its original, standardized procedure, and thus that patients have sufficiently spared motor abilities to complete the test.
本研究旨在通过以爱丁堡认知行为 ALS 筛查(ECAS)为金标准,评估额叶评估量表(FAB)在非痴呆型肌萎缩侧索硬化症(ALS)患者中的诊断特性,并通过检查其可操作性及其与运动功能测量的得分之间的相关性来实现。
连续纳入 348 例患者进行 ECAS 和 FAB 检查。考虑了疾病严重程度(ALSFRS-R)、病程、进展率(ΔFS)和分期(通过 King's 和 Milano-Torino 系统)。比较了不同临床分期的 FAB 可操作性率和低于截断值的 FAB 评分的发生率;回归模型允许测试在 ECAS-总评分之外,运动特征是否可以预测 FAB 不可操作性和 FAB 评分缺陷的概率。对结合的缺陷性 ECAS-执行和 ECAS-流畅性评分进行了内在和后测诊断。
85.3%的患者能够完成 FAB。FAB 可操作性率随着临床分期的进展而降低,而低于截断值的 FAB 评分的发生率并未降低。FAB 不可操作性的概率仅由较低的 ALSFRS-R-延髓和 ALSFRS-R-上肢评分预测;没有运动特征,但 ECAS-总评分可以预测 FAB 得分低于截断值。原始和调整后的 FAB 评分均具有较高的准确性(AUC 分别为.85 和.81),并且具有良好的内在和后测特性。
FAB 具有检测 ALS 患者执行功能缺陷的最佳诊断性能,前提是可以按照其原始的标准化程序进行操作,因此患者有足够的运动能力来完成测试。